Completion of Euros 7.25 Million Round of Financing in Nautilus

Nautilus Biotech a private protein pharmaceutical company announced the completion of a Euro 7.25 million round of financing with a syndicate led by Auriga Partners. Along with existing investors, Matignon Technologies, Funds managed by Edmond Rothschild Investment Partners, FCJE (CDC PME, Caisse de Depots) and Pre-IPO Invest, Auriga Partners, 123 Venture and Creabilis Biotech have invested in Nautilus. Nautilus will use the proceeds to take its lead product Belerofon (improved IFNa) into an IND and move its next-generation, long-lasting, non-pegylated IFNb into advanced pre-clinical development.

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=19223320&full=1)